Taysha Gene Therapies, Inc. Cash
Taysha Gene Therapies, Inc. (TSHA) had Cash of $197.40 million as of 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:Cash · last filed 2021-08-16
- 2021-06-30: Cash $197.40M.
- 2021-03-31: Cash $228.70M.
| Period end | Cash |
|---|---|
| 2021-06-30 | $197.40M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $228.70M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |